NASDAQ · AMGNHealthcareBiotechnology

Amgen financials

$423.64+1.32%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Q2 '25
Jun 30
Q1 '25
Mar 31
Q4 '24
Dec 31
Q3 '24
Sep 30
Q2 '24
Jun 30
Q1 '24
Mar 31
Q4 '23
Dec 31
Q3 '23
Sep 30
Revenue$10.05B$8.62B$9.87B$9.56B$9.18B$8.15B$9.09B$8.50B$8.39B$7.45B$8.20B$6.90B
Gross profit$7.24B$5.87B$6.89B$6.47B$6.17B$5.18B$5.97B$5.19B$5.15B$4.25B$5.08B$5.10B
Gross margin72.0%68.2%69.8%67.8%67.2%63.6%65.7%61.1%61.4%57.0%62.0%73.8%
Operating income$3.51B$2.67B$2.72B$2.53B$2.66B$1.18B$2.31B$2.05B$1.91B$991.0M$1.27B$2.02B
Net income$2.38B$1.82B$1.33B$3.22B$1.43B$1.73B$627.0M$2.83B$746.0M-$113.0M$767.0M$1.73B
Net margin23.6%21.1%13.5%33.7%15.6%21.2%6.9%33.3%8.9%−1.5%9.4%25.1%
Diluted EPS$4.37$3.34$2.45$5.93$2.65$3.20$1.15$5.22$1.38$-0.21$1.42$3.22
EBITDA$4.63B$3.78B$3.85B$3.83B$4.00B$2.56B$3.71B$3.44B$3.31B$2.39B$1.27B$2.92B
Operating cash flow$4.00B$2.19B$1.60B$4.68B$2.28B$1.39B$4.77B$3.57B$2.46B$689.0M$538.0M$2.76B
Free cash flow$3.49B$1.48B$961.0M$4.25B$1.91B$980.0M$4.40B$3.31B$2.22B$459.0M$289.0M$2.51B
Diluted shares544.0M544.0M544.0M542.0M541.0M541.0M545.0M542.0M541.0M536.0M539.0M538.0M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$13.99B$12.04B$9.13B$9.45B$8.03B$8.81B
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$57.30B$57.32B$54.60B$54.59B$56.20B$57.38B
Total assets$95.64B$92.50B$90.59B$90.14B$87.90B$89.37B
Total liabilities$83.95B$83.31B$81.93B$80.52B$80.47B$83.16B
Shareholders' equity$11.69B$9.19B$8.66B$9.62B$7.43B$6.21B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology